Chardan Capital Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price lifted by Chardan Capital from $300.00 to $325.00 in a research note released on Friday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Other analysts also recently issued research reports about the stock. Citigroup raised their price objective on shares […]
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price lifted by Chardan Capital from $300.00 to $325.00 in a research note released on Friday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Other analysts also recently issued research reports about the stock. Citigroup raised their price objective on shares […]
